
Diabetic patients with ovarian cancer who took the drug metformin for their diabetes had a better survival rate than patients who did not take it. When Mayo Clinic researchers analyzed factors such as the patients’ body mass index, the severity of the cancer, type of chemotherapy and quality of surgery, they found that patients taking metformin were nearly four times likelier to survive, compared with those not taking the medication. The results may pave the way for using metformin in large-scale randomized trials in ovarian cancer. Click here for news release
During breaks from his doctoral research in London, Richard Vile, Ph.D., would visit a pediatric brain tumor clinic next to his lab for inspiration. Seeing children ...
Gastroesophageal reflux disease (GERD) is one of the most common digestive disorders in the world. It happens when acid comes up from the stomach, which is ...
DEAR MAYO CLINIC: A 62-year-old man I worked with was diagnosed with stomach cancer earlier this year. He reportedly was feeling full even after eating ...